Status:
COMPLETED
Presenteeism in Severe Asthma Treated by Biotherapyasthma
Lead Sponsor:
University Hospital, Lille
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
Severe asthma is a condition characterized by a lower sensitivity to high doses of inhaled corticosteroids combined with a second controller, most often a long-acting bronchodilator. It concerns appro...
Eligibility Criteria
Inclusion
- Severe asthma defined as the use of a high doses of inhaled corticosteroids combined with a second controller (GINA 4) and / or oral corticosteroid therapy \> 50% of the year
- Eligible for biotherapy according to the investigator's decision
- Holders of an employment contract for at least 8 days
- Written non-opposition to participate in the study after information
- Social protection affiliation
Exclusion
- Existence of another chronic pulmonary disease (bronchiectasis, COPD, diffuse interstitial lung disease, neuromuscular pathology, etc.) or cardiac (cardiac rhythm disorder, ischemic heart disease, etc.) significant according to the investigator's judgment
- Psychiatric disorder
- Pregnancy
- Persons under guardianship
Key Trial Info
Start Date :
January 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 10 2024
Estimated Enrollment :
174 Patients enrolled
Trial Details
Trial ID
NCT04463589
Start Date
January 1 2021
End Date
June 10 2024
Last Update
December 23 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hop Calmette Chu Lille
Lille, France